The Form 144 signals an officer's intent to sell a small number of shares from vested RSUs, consistent with routine tax-related or diversification selling. The prior sales in September 2026 suggest a pattern of periodic dispositions. No material impact on the stock is expected.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $961.26entry
- T+1 · 14d ago +1.26%α +0.96% · $973.36
- T+5 · 8d ago −4.30%α −4.37% · $919.96
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Marion McCourt, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 1,132 shares of common stock, valued at approximately $984,195 based on the filing date price. The shares were acquired via restricted stock award vesting in December 2023. This is a routine insider sale notice representing a small fraction of the company's $83.7B market cap.
Key Facts
- Marion McCourt, an officer of Regeneron, filed Form 144 to sell 1,132 shares of common stock.
- Estimated sale value is approximately $984,195 based on the filing date price of ~$869 per share.
- Shares were acquired on 12/12/2023 via restricted stock award vesting from the issuer.
- The sale is proposed to occur on or after 10/30/2026 on Nasdaq.
- The filing also notes two prior sales by McCourt in September 2026: 1,215 shares on 09/02/2026 and 1,131 shares on 09/03/2026.
- The proposed sale represents about 0.001% of Regeneron's $83.7B market cap.
Financial Impact
Proposed sale of 1,132 shares valued at ~$984,195, negligible relative to $83.7B market cap.
Risk Factors
- Insider selling could increase if additional officers file similar notices, but this single filing is immaterial.
- The sale may not occur; Form 144 is an intent notice, not a completed transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001108 |
| Document: 0001969223-26-001108-index.html | 0001969223-26-001108 |
| Document: 0001969223-26-001108.txt | 0001969223-26-001108 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers